REYON Pharmaceutical Co., Ltd. announced that it has received KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm
July 20, 2017
Share
On July 21, 2017, REYON Pharmaceutical Co., Ltd. (KOSE:A102460) closed the transaction.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON Pharmaceutical Co., Ltd. announced that it has received KRW 40 billion in funding from Mirae Asset Daewoo Co., Ltd., KDB Capital Corp., Eum Private Equity, Industrial Bank of Korea, Investment Arm
REYON PHARMACEUTICAL CO., LTD. 
